Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: A phase II study

M. Javle, J. Yu, C. Garrett, A. Pande, B. Kuvshinoff, A. Litwin, J. Phelan, J. Gibbs, R. Iyer

Research output: Contribution to journalArticle

29 Scopus citations

Abstract

A total of 50 patients with advanced pancreatic cancer were enrolled in a phase II study of bevacizumab 15mgkg1, capecitabine 1300mgm 2 daily for 2 weeks and gemcitabine 1000mgm2 weekly 2 times; cycles were repeated every 21 days. Radiological response rate was 22; progression-free survival and over survival were 5.8 and 9.8 months respectively. Grade 3 or 4 toxicities included neutropaenia (22), thrombocytopaenia (14), thromboembolic events (12), hypertension (8) and haemorrhage (6).

Original languageEnglish (US)
Pages (from-to)1842-1845
Number of pages4
JournalBritish Journal of Cancer
Volume100
Issue number12
DOIs
StatePublished - Jun 16 2009

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: A phase II study'. Together they form a unique fingerprint.

  • Cite this

    Javle, M., Yu, J., Garrett, C., Pande, A., Kuvshinoff, B., Litwin, A., Phelan, J., Gibbs, J., & Iyer, R. (2009). Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: A phase II study. British Journal of Cancer, 100(12), 1842-1845. https://doi.org/10.1038/sj.bjc.6605099